A Biomarker Combining Imaging and Neuropsychological Assessment for Tracking Early Alzheimer's Disease in Clinical Trials

Publisher： Bentham Science Publishers

E-ISSN： 1875-5828|15|5|429-442

ISSN： 1567-2050

Source： Current Alzheimer Research, Vol.15, Iss.5, 2018-03, pp. : 429-442

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Automated neuropsychological assessment metrics (ANAM) measures of cognitive effects of Alzheimer's disease

By Levinson D.  

Archives of Clinical Neuropsychology, Vol. 20, Iss. 3, 2005-05 ,pp. : 403-408

Oxford University Press

Access to resources Recommend Favorite

Amyloid Beta-Weighted Cortical Thickness: A New Imaging Biomarker in Alzheimer's Disease

By  

Current Alzheimer Research, Vol. 12, Iss. 6, 2015-01 ,pp. : 563-571

Bentham Science Publishers

Access to resources Recommend Favorite

Cerebrospinal Fluid proNGF: A Putative Biomarker for Early Alzheimer’s Disease

By  

Current Alzheimer Research, Vol. 13, Iss. 7, 2016-07 ,pp. : 800-808

Bentham Science Publishers

Access to resources Recommend Favorite

Use of Functional Magnetic Resonance Imaging in the Early Identification of Alzheimer's Disease

By Wierenga Christina   Bondi Mark  

Neuropsychology Review, Vol. 17, Iss. 2, 2007-06 ,pp. : 127-143

Springer Publishing Company

Access to resources Recommend Favorite

Atypical and typical presentations of Alzheimer's disease: a clinical, neuropsychological, neuroimaging and pathological study of 13 cases

By Galton C.J.  

Brain, Vol. 123, Iss. 3, 2000-03 ,pp. : 484-498

Oxford University Press

Access to resources Recommend Favorite